Skip to main navigation
  • About
    • Leaders
  • Our Science
    • Pipeline
    • Nemvaleukin Alfa
    • Il-18
    • Il-12
  • Publications
Mural Oncologylogo
  • Clinical Trials
  • Investors & News
    • Press Releases
    • Events & Presentations
    • Financials & Filings
    • Stock Information
    • Governance
  • Careers
    • Job Opportunities
Mural Oncology logo
  • About
    • Leaders
  • Our Science
    • Pipeline
    • Nemvaleukin Alfa
    • Il-18
    • Il-12
  • Publications
  • Clinical Trials
  • Investors & News
    • Investors Home
    • Press Releases
    • Events & Presentations
    • Financials & Filings
    • Stock Information
    • Governance
  • Careers
    • Job Opportunities
  • About
    • Leaders
  • Our Science
    • Pipeline
    • Nemvaleukin Alfa
    • Il-18
    • Il-12
  • Publications
  • Clinical Trials
  • Investors & News
    • Investors Home
    • Press Releases
    • Events & Presentations
    • Financials & Filings
    • Stock Information
    • Governance
  • Careers
    • Job Opportunities

Press
Releases

  • Investors Home
  • Press Releases
  • Events & Presentations
  • Financials & Filings
  • Stock Information
  • Governance
Jan 08, 2024
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
Pagination
  • First page << First
  • Previous page < Previous
  • …
  • Page 2
  • Page 3
  • Current page 4
Print page >>
Contact us >>
RSS >>
Email alerts >>
  • About
  • Our Science
  • Publications
  • Clinical Trials
  • Investors & News
  • Careers
  • Contact
  • About
  • Our Science
  • Publications
  • Clinical Trials
  • Investors & News
  • Careers
  • Contact

© 2024 Mural Oncology. All Rights Reserved.

Mural Oncology logo
  • Privacy Policy
  • Terms of Use
  • Site Map
  • Privacy Policy
  • Terms of Use
  • Site Map
Mural Oncology on LinkedIn Mural Oncology on Twitter